New antibody drug shows promise in early arthritis trial
NCT ID NCT03574545
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tested two versions of an experimental drug called ianalumab in 48 adults with active rheumatoid arthritis. The goal was to see if the two forms are similar enough in safety and how the body processes them. Participants received multiple injections, and researchers tracked side effects and drug levels in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ianalumab (a lab-made antibody that targets B cells)
What this could lead to
If successful, this could help confirm that the two forms of ianalumab are similar enough to use in larger trials for rheumatoid arthritis.
What could go wrong
This is a very early Phase 1 study with only 48 people, focused on safety and drug levels, not on whether the drug actually improves arthritis symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Berlin, 10117, Germany
-
Novartis Investigative Site
Amman, 11941, Jordan